Silvia Bordel-Vozmediano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Silvia Bordel-Vozmediano has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Víctor Manuel Pérez García
Mathematical Oncology Laboratory (MOLAB), Instituto de Matemática Aplicada a la Ciencia y la Ingeniería, University of Castilla-La Mancha
3 shared publications - Ana Ortiz de Mendivil
Hospital Universitario HM Sanchinarro
1 shared publication Ana Ramos
Hospital Universitario 12 de Octubre
1 shared publication- Beatriz Asenjo
Hospital Regional Universitario de Malaga
1 shared publication - Beatriz Ocaña-Tienda
Bioinformatics Unit, Spanish National Cancer Research Centre, Madrid, Spain
1 shared publication - Belen Luque
University of Castile-La Mancha
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by Springer Nature in Research Square
A multicentre longitudinal brain metastasis imaging dataset with lesion segmentations and clinical data
Brain metastases exhibit substantial variability in lesion burden, morphology and treatment response. Longitudinal imaging linked to lesion annotations and clinical histories can support quantitative studies of this heterogeneity. We describe a multicentre dataset from seven Spanish hospitals comprising 443 patients diagnosed between 2007 and 2022, with follow-up imaging for 216 patients. The collection contains 2842 magnetic resonance image, including 1092 three dimensional (3D) contrast-enhanced T1-weighted, 833 T2-weighted and 917 FLAIR (fluid-attenuated inversion recovery) images. Semiautomatic 3D-segmentation with expert review provides annotations for 1291 unique lesions represented by 2303 lesion observations across imaging time points. Separate labels identify contrast-enhancing and non-enhancing or necrotic tumour components, and lesion identifiers are maintained during follow-up. Accompanying records describe primary tumour characteristics, treatments, imaging dates and clinical outcomes, together with acquisition metadata and 107 morphological and radiomic features. The dataset supports research on lesion detection and segmentation, longitudinal response assessment, imaging biomarkers and mathematical models of brain metastasis growth and treatment response.
- 9 November 2026
- Published by Springer Nature in Research Square
Open AccessA multicentre longitudinal brain metastasis imaging dataset with lesion segmentations and clinical data
Brain metastases exhibit substantial variability in lesion burden, morphology and treatment response. Longitudinal imaging linked to lesion annotations and clinical histories can support quantitative studies of this heterogeneity. We describe a multicentre dataset from seven Spanish hospitals comprising 443 patients diagnosed between 2007 and 2022, with follow-up imaging for 216 patients. The collection contains 2842 magnetic resonance image, including 1092 three dimensional (3D) contrast-enhanced T1-weighted, 833 T2-weighted and 917 FLAIR (fluid-attenuated inversion recovery) images. Semiautomatic 3D-segmentation with expert review provides annotations for 1291 unique lesions represented by 2303 lesion observations across imaging time points. Separate labels identify contrast-enhancing and non-enhancing or necrotic tumour components, and lesion identifiers are maintained during follow-up. Accompanying records describe primary tumour characteristics, treatments, imaging dates and clinical outcomes, together with acquisition metadata and 107 morphological and radiomic features. The dataset supports research on lesion detection and segmentation, longitudinal response assessment, imaging biomarkers and mathematical models of brain metastasis growth and treatment response.
- Open Access
Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and in silico trials
Radiopharmaceutical therapy (RPT) has rapidly evolved into a key precision-oncology modality, with radioligands now approved or in late-stage development for multiple solid tumors, including neuroendocrine and prostate cancers. RPT with [177Lu]Lu-PSMA (Prostate-Specific Membrane Antigen) has recently been approved as a life-prolonging treatment for metastatic castration-resistant prostate cancer (mCRPC), but its clinical use still relies on non-personalized, empirically chosen fixed schedules. Here, we develop a mechanistic, patient-personalizable mathematical model simulating mCRPC response and organ-at-risk toxicity during [177Lu]Lu-PSMA RPT. The model integrates tumor growth dynamics, radiobiological response, and organ-resolved pharmacokinetics inferred from mass data and standardized uptake values obtained from positron emission tomography studies. Parameters were derived from the literature, although the framework allows personalization by fitting to patient-specific data such as imaging and prostate-specific antigen levels. Using virtual patient (VP) cohorts generated via stochastic parameter sampling, we conducted in silico trials and validated the model by comparing simulated outcomes with published dosimetry and survival data for [177Lu]Lu-PSMA trials. We then explored dosing and scheduling strategies to optimize efficacy-toxicity trade-offs. Consolidated regimens with fewer, higher-activity injections improved overall survival (OS) in silico but increased OAR toxicity, especially in kidneys. Cycle length had a weaker influence on OS within a 2-9 week window, while it clearly affected toxicity, whereas excessive delays (>12 weeks) markedly reduced efficacy. Global sensitivity analysis identified tumor growth, uptake, and radiosensitivity parameters as key drivers of interpatient variability, and convergence testing confirmed robustness with respect to VP cohort size. These methodological findings illustrate how mechanistic modeling and in silico trials can inform the design and personalization of RPT regimens.
Open AccessRadiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and in silico trials
Radiopharmaceutical therapy (RPT) has rapidly evolved into a key precision-oncology modality, with radioligands now approved or in late-stage development for multiple solid tumors, including neuroendocrine and prostate cancers. RPT with [177Lu]Lu-PSMA (Prostate-Specific Membrane Antigen) has recently been approved as a life-prolonging treatment for metastatic castration-resistant prostate cancer (mCRPC), but its clinical use still relies on non-personalized, empirically chosen fixed schedules. Here, we develop a mechanistic, patient-personalizable mathematical model simulating mCRPC response and organ-at-risk toxicity during [177Lu]Lu-PSMA RPT. The model integrates tumor growth dynamics, radiobiological response, and organ-resolved pharmacokinetics inferred from mass data and standardized uptake values obtained from positron emission tomography studies. Parameters were derived from the literature, although the framework allows personalization by fitting to patient-specific data such as imaging and prostate-specific antigen levels. Using virtual patient (VP) cohorts generated via stochastic parameter sampling, we conducted in silico trials and validated the model by comparing simulated outcomes with published dosimetry and survival data for [177Lu]Lu-PSMA trials. We then explored dosing and scheduling strategies to optimize efficacy-toxicity trade-offs. Consolidated regimens with fewer, higher-activity injections improved overall survival (OS) in silico but increased OAR toxicity, especially in kidneys. Cycle length had a weaker influence on OS within a 2-9 week window, while it clearly affected toxicity, whereas excessive delays (>12 weeks) markedly reduced efficacy. Global sensitivity analysis identified tumor growth, uptake, and radiosensitivity parameters as key drivers of interpatient variability, and convergence testing confirmed robustness with respect to VP cohort size. These methodological findings illustrate how mechanistic modeling and in silico trials can inform the design and personalization of RPT regimens.
- Open Access
- 11 June 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 194, 110427
Geometric immunosuppression in CAR T-cell treatment: Insights from mathematical modeling
- 11 June 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 194, 110427
Open AccessGeometric immunosuppression in CAR T-cell treatment: Insights from mathematical modeling
- Open Access
Geometric immunosuppression in CAR-T cell treatment: Insights from mathematical modeling
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a promising treatment for hematological malignancies, offering a targeted approach to cancer treatment. Understanding the complexities of CAR-T cell therapy within solid tumors poses challenges due to the intricate interactions within the tumor microenvironment. Mathematical modeling may serve as a valuable tool to unravel the dynamics of CAR-T cell therapy and improve its effectiveness in solid tumors. This study aimed to investigate the impact of spatial aspects in CAR-T therapy of solid tumors, utilizing cellular automata for modeling purposes. Our main objective was to deepen our understanding of treatment effects by analyzing scenarios with different spatial distributions and varying the initial quantities of tumor and CAR-T cells. Tumor geometry significantly influenced treatment efficacy in-silico, with notable differences observed between tumors with block-like arrangements and those with sparse cell distributions, leading to the concept of immune suppression due to geometrical effects. This research delves into the intricate relationship between spatial dynamics and the effectiveness of CAR-T therapy in solid tumors, highlighting the relevance of tumor geometry in the outcome of cellular immunotherapy treatments. Our results provide a basis for improving the efficacy of CAR-T cell treatments by combining them with other ones reducing the density of compact tumor areas and thus opening access ways for tumor killing T-cells.
Open AccessGeometric immunosuppression in CAR-T cell treatment: Insights from mathematical modeling
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a promising treatment for hematological malignancies, offering a targeted approach to cancer treatment. Understanding the complexities of CAR-T cell therapy within solid tumors poses challenges due to the intricate interactions within the tumor microenvironment. Mathematical modeling may serve as a valuable tool to unravel the dynamics of CAR-T cell therapy and improve its effectiveness in solid tumors. This study aimed to investigate the impact of spatial aspects in CAR-T therapy of solid tumors, utilizing cellular automata for modeling purposes. Our main objective was to deepen our understanding of treatment effects by analyzing scenarios with different spatial distributions and varying the initial quantities of tumor and CAR-T cells. Tumor geometry significantly influenced treatment efficacy in-silico, with notable differences observed between tumors with block-like arrangements and those with sparse cell distributions, leading to the concept of immune suppression due to geometrical effects. This research delves into the intricate relationship between spatial dynamics and the effectiveness of CAR-T therapy in solid tumors, highlighting the relevance of tumor geometry in the outcome of cellular immunotherapy treatments. Our results provide a basis for improving the efficacy of CAR-T cell treatments by combining them with other ones reducing the density of compact tumor areas and thus opening access ways for tumor killing T-cells.